Orforglipron linked to about 13% weight loss in adults 65 and older in trial analysis

A post hoc subgroup analysis of two Phase 3 trials reports that adults 65 and older taking orforglipron lost about 13% of their body weight at the highest dose tested, results the authors describe as broadly consistent with those seen in younger participants ^[1]. The analysis was published in the September 2026 issue of the journal Obesity Pillars ^[1].

The paper pooled participants aged 65 and older from ATTAIN-1, a trial in people with obesity, and ATTAIN-2, a trial in people with obesity and type 2 diabetes ^[1]. Of 616 randomized participants in that age group, 613 were treated: 118 received orforglipron 5.5 mg, 135 received 9 mg, 146 received 17.2 mg and 214 received placebo, all once daily as an addition to a healthy diet and physical activity ^[1].

The main endpoint was percent change in body weight from baseline to Week 72 ^[1]. Among older participants in ATTAIN-1, the average change was −7.9% (95% confidence interval −10.0 to −5.9) with 5.5 mg, −11.3% (−13.4 to −9.3) with 9 mg and −13.0% (−15.7 to −10.4) with 17.2 mg, compared with −1.6% (−3.2 to 0.1) with placebo. All dose comparisons against placebo had p values below 0.001 ^[1].

In ATTAIN-2, the same endpoint was −7.5% (−9.1 to −5.9) with 5.5 mg, −8.3% (−9.7 to −6.8) with 9 mg and −12.2% (−13.9 to −10.6) with 17.2 mg, versus −2.3% (−3.1 to −1.4) with placebo, again with p values below 0.001 ^[1].

The authors reported comparable findings in participants younger than 65 and described the reductions in body weight and HbA1c, a measure of average blood sugar, in the older group as clinically meaningful ^[1]. Gastrointestinal side effects were the most common events with orforglipron and were generally mild to moderate in severity, with safety findings described as consistent across age groups and with the overall ATTAIN-1 and ATTAIN-2 results ^[1].

Why it matters for patients

Older adults have fewer weight-management options in some cases: the paper notes that fasting requirements for some oral therapies and needle avoidance may limit choices for people 65 and older ^[1]. Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist taken once daily ^[1]. One secondary account says the pill can be taken without food or water restrictions, but the journal analysis does not describe dosing instructions of that kind ^[1][2].

These are subgroup results, not a new standalone test of the drug. Post hoc analyses of this type are hypothesis-generating and were not powered as independent efficacy tests, so the numbers are best read as a signal about how older adults responded inside two larger trials. The figures are group averages; the paper does not say how many people in each arm reached any particular weight-loss threshold.

The paper does not report effects on muscle mass, physical function, falls or quality of life, which are questions that often matter in this age group. Safety beyond 72 weeks has not been reported.

The journal analysis does not address approval status, price or insurance coverage. A secondary account describes 17.2 mg as the highest approved dose and refers to a Medicare program with a $50 monthly copay starting July 1, 2026 ^[2]; those details do not appear in the journal paper and are not confirmed there. The same account uses the brand name Foundayo for orforglipron ^[2].

What is not yet known

Whether a dedicated prospective trial of orforglipron in older adults will be run has not been disclosed; the paper reports only the post hoc analysis of existing trial data ^[1]. Head-to-head comparisons between orforglipron and injected GLP-1 drugs in this age group have not been reported, and it is not established from these results how the drug affects frailty, muscle strength or the ability to stay independent. The trial registrations listed with the analysis are ATTAIN-1 (NCT05869903) and ATTAIN-2 (NCT05872620) ^[1].